Corcept has reached its take-profit ceiling at $83.09 with a negative risk/reward and 15% downside; two consecutive earnings misses have broken the prior beat streak, and a put/call ratio of 4.44 with 11% short interest signals heavy bearish market positioning — making the current setup unfavorable despite strong momentum readings.
Thesis pillars
- Price At Take Profit Negative Asymmetry→Stable
- Two Consecutive Earnings Misses→Stable
- Elevated Put Call High Short Interest→Stable
- +2 more pillars — see the Why tab for full reasoning
Corcept Therapeutics Incorporat (CORT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. At $91.61, A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Counterparty: Curant; Concentration risk — Product: Products.
Corcept Therapeutics markets Korlym (mifepristone) and an authorized generic in the US for Cushing's syndrome (hypercortisolism) since 2012, with all revenue from these products collected by specialty pharmacy Curant Health. A relacorilant NDA for ovarian cancer has a PDUFA date... Read more
Sell if holding. At $91.61, A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Counterparty: Curant; Concentration risk — Product: Products. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.4/10, high confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 25d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Corcept Therapeutics Incorporat
About Corcept Therapeutics Incorporat
Corcept Therapeutics has marketed Korlym (mifepristone) in the United States for hypercortisolism since 2012, adding an authorized generic in June 2024; all revenue flows from these two products for Cushing's syndrome. On December 30, 2025, the FDA issued a Complete Response Letter declining to approve relacorilant for hypercortisolism, while a second relacorilant NDA for ovarian cancer — accepted in September 2025 — carries a PDUFA date of July 11, 2026.
Korlym and its generic are distributed through Curant Health Georgia, LLC, which became the primary specialty pharmacy vendor in Q4 2025 following termination of the Optime Care relationship in October 2025; the Curant agreement runs to June 2028. Curant collects payments from insurers representing more than 99% of Corcept's revenue. The company's sales model targets physicians via sales representatives and medical science liaisons, with patient assistance programs funding co-pay support. Payer mix includes Medicare and Medicaid; the Inflation Reduction Act's Part D price negotiation program currently exempts orphan drugs indicated for only one rare disease — covering Korlym — and drugs with less than $200 million in annual Medicare expenditures. Generic competition from Teva entered in January 2024; the Federal Circuit affirmed no patent infringement on February 19, 2026, and litigation settlements with Sun Pharmaceutical and Hikma Pharmaceuticals allow those companies to enter commercially if Teva remains in the market.
Show full overview
The December 30, 2025 Complete Response Letter for the hypercortisolism NDA is the most immediate binary risk to Corcept's pipeline; the FDA required additional efficacy evidence despite the GRACE trial meeting its primary endpoint and the GRADIENT trial providing confirmatory data in patients with adrenal-etiology disease. The ovarian cancer indication carries a separate risk profile: the ROSELLA trial met dual primary endpoints for progression-free survival (hazard ratio 0.70, March 2025) and overall survival (hazard ratio 0.65, January 2026), supporting the July 11, 2026 PDUFA date, but any additional FDA request before that date could delay approval.
See also: Healthcare · Biotechnology
From Corcept Therapeutics Incorporat's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-07Recent Developments — Corcept Therapeutics Incorporat
Latest news
- NEWS Lifyorli’s Pivotal ROSELLA Data and FDA Nod Might Change The Case For Investing In Corcept (CORT) - Sahm — Sahm positive
- NEWS Corcept Therapeutics (CORT) Inspires Confidence with ROSELLA Phase 3 Survival Data - Insider Monkey — Insider Monkey positive
- NEWS Corcept Earnings: What To Look For From CORT - StockStory — StockStory neutral
- NEWS Why investors strapped a rocket to Corcept Therapeutics stock on Wednesday - MSN — MSN positive
- NEWS Why Corcept Therapeutics Stock Is Sinking Today - TipRanks — TipRanks negative
Generated 2026-07-07T11:21:38Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyCurant10-K Item 1A: 'Curant, dispenses our Products and performs related pharmacy and patient support services, including the collection of payments from insurers representing more than 99 percent of our revenue'
- HIGHProductProducts10-K Item 1A: 'Our ability to generate revenue and to fund our commercial operations and development programs is dependent on the sale of our Products to treat patients with hypercortisolism'
- HIGHpipelinerelacorilant10-K Item 1: 'On December 30, 2025, the FDA issued a Complete Response Letter ("CRL") declining to approve relacorilant'
Material Events(8-K, last 90d)
- 2026-05-28Item 5.02LOWOn May 21, 2026, shareholders approved an Amendment to the Corcept Therapeutics 2024 Incentive Award Plan, adding 8,000,000 shares to the plan. No officer departure or appointment disclosed under this item.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $91.61, A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Counterparty: Curant; Concentration risk — Product: Products. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $85.20. Score 4.4/10, high confidence.
Take-profit target: $90.97 (-0.7% upside). Prior stop was $85.20. Stop-loss: $85.20.
Concentration risk — Counterparty: Curant; Concentration risk — Product: Products; Analyst target reached - limited upside remaining.
Corcept Therapeutics Incorporat trades at a P/E of 257.7 (forward 36.2). TrendMatrix value score: 3.9/10. Verdict: Sell.
12 analysts cover CORT with a consensus score of 4.0/5. Average price target: $88.
What does Corcept Therapeutics Incorporat do?Corcept Therapeutics markets Korlym (mifepristone) and an authorized generic in the US for Cushing's syndrome...
Corcept Therapeutics markets Korlym (mifepristone) and an authorized generic in the US for Cushing's syndrome (hypercortisolism) since 2012, with all revenue from these products collected by specialty pharmacy Curant Health. A relacorilant NDA for ovarian cancer has a PDUFA date of July 11, 2026; a separate relacorilant NDA for hypercortisolism received a Complete Response Letter on December 30, 2025.